Reported Earlier, United Therapeutics Prevails In Delaware Court Ruling Finding Liquidia Infringes Two Claims Of Patent On Inhaled Treprostinil For PH-ILD Via Yutrepia Marketing

United Therapeutics has won a Delaware court ruling that finds Liquidia infringes on two patent claims related to inhaled treprostinil for pulmonary hypertension associated with interstitial lung disease (PH-ILD) via its Yutrepia marketing. Following this decision, United Therapeutics is seeking an order for the FDA to withdraw approval of Liquidia's new drug application for Yutrepia, which could lead to its removal from the U.S. market. Additionally, the company plans to pursue monetary damages for past infringement, potentially including royalties on Yutrepia's past sales.